Neuroprotective properties of statins in cerebral ischemia and stroke

Stroke

Volumn 30, Issue 9, 1999, Pages 1969-1973

  Vaughan, Carl J ^a   Delanty, Norman ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Endothelium; HMG CoA reductase inhibitors; Inflammation; Neuroprotection; Nitric oxide

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; STATIN;

ATHEROSCLEROTIC PLAQUE; BRAIN CIRCULATION; BRAIN ISCHEMIA; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY; ENZYME ACTIVITY; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0032826065     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.9.1969     Document Type: Review

References (40)

1. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen 3D, for the MRFIT Research Group. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
2. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective studies. Lancet. 1995:346:1647-1653.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996:335:1001-1009.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
5. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28: 946-950.
6. Crouse JR III, Byington RP, Hocn HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157: 1305-1310.
7. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovem ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid arteries (PLAC-II). Am J Cardiol. 1995;75: 455-459.
8. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997:28:2315-2320.
9. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996:348:1079-1082.
10. Bryan RN, Wells SW, Miller TJ, Elster AD, Jungreis CA, Poirier VC, Lind BK, Manolio TA. Infarct-like lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly: data from the Cardiovascular Health Study. Radiology. 1997:202:47-54.
11. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke. 1997:28:1283-1288.
12. Hu SX, Sheng WS, Peterson PK, Chao CC. Differential regulation by cytokines of human astrocyte nitric oxide production. Glia. 1995;15: 491-494.
13. Forster C, Clark HB, Ross ME, ladecola C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol. 1999; 97:215-220.
14. Huang PL, Huang ZH, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996:16:981-987.
15. ladecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischémie brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci. 1997;17: 9157-9164.
16. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita T. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
17. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997:95:1126-1131.
18. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc NatlAcadSci USA. 1998;95:8880-8885.
19. Ding M, St Pierre BA, Parkinson JF, Medberry P, Wong JL, Rogers NE, Ignarro LJ, Merrill JE. Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia: a kinetic analysis. JBiol Chem. 1997;272:11327-11335.
20. Pahan K, Sheikh FG, Namboodiri AMS, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997; 100: 2671-2679.
21. Pantoni L, Sorti C, Inzitari D. Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler Thromb Vase Biol. 1998:18:503-513.
22. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vase Biol. 1997;17:1521-1526.
23. Lehr HA, Seemuller J, Hubner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor. Arterioscler Thromb. 1993;13: 1013-1018.
24. Weber C, Erl W. Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CDllb expression and CDllb-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cordial. 1997:30:1212-1217.
25. Chiloeches A, Usera F, Lasa M, Ropero S, Montes A, Toro MJ. Effect of mevalonate availability on the association of G-protein a-subunits with the plasma membrane in GK.C, cells. FEBS Lett. 1997;401:68-72.
26. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischémie cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25: 869-876.
27. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin l (1L-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984:160:618-623.
28. Liu T, McDonnell PC, Young PR, White RF, Siren AL, Hallenbeck JM, Barone FC, Feuerstein GZ. Interleukin-I mRNA expression in ischémie rat cortex. Stroke. 1993;24:1746-1751.
29. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP. Altered neuronal and microglial responses to excitotoxic and ischémie brain injury in mice lacking TNF receptors. Nat Med. 1996:2:788-794.
30. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998:4:78-83.
31. Loddick SA, Rothwell NJ. Neuroprotective effects of recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab. 1996;16:932-940.
32. Delanty N, Dichter MA. Oxidative injury in the nervous system. Ada Neural Scand. 1998;98:145-153.
33. Chan PH. Role of oxidants in ischémie brain damage. Stroke. 1996;27: 1124-1129.
34. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue to the "response to injury" hypothesis. Circulation. 1997:95:1760-1763.
35. Hussein O, Schlezinger SA, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to LDL. Atherosclerosis. 1997;128:11-18.
36. Chen L, Haught WH, Yang B, Saldeen TCP, Parthasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997;30: 569-575.
37. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998:138:271-280.
38. Human JA, Ubbink JB, Jerling JJ, Delport, Vermaak WJH, Vorster HH, Lagendijk J, Potgieter HC. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chem Acta. 1997;263:67-77.
39. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J, Ye C-Q, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc NatlAcadSci USA. 1990;87:8931-8934.
40. Matthews RT, Yang L, Browne S, Baik M, Béai MF. Coenzyme Q,0 administration increases brain mitochondria! concentrations and exerts neuroprotective effects. Proc Nail Acad Sei USA. 1998;95:8892-8897.